Foxo technologies unveils plans for new direct-to consumer offering combining the company's epigenetic data with the power of ai

Minneapolis--(business wire)--foxo technologies inc. (nyse american: foxo) (“foxo” or the “company”), a leader in the field of commercializing epigenetic biomarker technology, today announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) foxo's machine learning models to analyze epigenetic biomarkers; (ii) the company's expertise and algorithms correlating epigenetic analysis with hea.
FOXO Ratings Summary
FOXO Quant Ranking